Promoting U ndetectable Equals U ntransmittable in Sub-Saharan Africa: Implication for Clinical Practice and ART Adherence

Int J Environ Res Public Health. 2020 Aug 25;17(17):6163. doi: 10.3390/ijerph17176163.

Abstract

In the last decade, reliable scientific evidence has emerged to support the concept that undetectable viral loads prevent human immunodeficiency virus (HIV). Undetectable equals untransmissible (U = U) is a simple message that everyone can understand. The success of this concept depends on strict adherence to antiretroviral therapy (ART) and the attainment of suppressed viral loads (VLs). To achieve U = U in sub-Saharan Africa (SSA), poor adherence to ART, persistent low-level viremia, and the emergence of drug-resistant mutants are challenges that cannot be overlooked. Short of a cure for HIV, U = U can substantially reduce the burden and change the landscape of HIV epidemiology on the continent. From a public health perspective, the U = U concept will reduce stigmatization in persons living with HIV (PLWHIV) in SSA and strengthen public opinion to accept that HIV infection is not a death sentence. This will also promote ART adherence because PLWHIV will aim to achieve U = U within the shortest possible time. This article highlights challenges and barriers to achieving U = U and suggests how to promote the concept to make it beneficial and applicable in SSA. This concept, if expertly packaged by policy-makers, clinicians, health service providers, and HIV control programs, will help to stem the tide of the epidemic in SSA.

Keywords: HIV; PLWHIV; U = U; adherence; anti-retroviral therapy; clinical practice; sub-Saharan Africa.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Africa South of the Sahara / epidemiology
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / methods*
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / psychology
  • HIV Infections / transmission*
  • HIV Infections / virology
  • Humans
  • Male
  • Medication Adherence
  • Viral Load / drug effects*

Substances

  • Anti-HIV Agents